131I–Tositumomab therapy as initial treatment for follicular lymphoma.
(2008). Available at: www.nlm.nih.gov/medlineplus/druginfo/natural/ patient-devilsclaw.html; cited
(2004). Cyclooxygenase-2 (c o x -2) expression in lymphomas. Leuk Lymphoma
Cyclooxygenase-2 (c o x -2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome.
(2008). Harpagophytum [Web article]. San Francisco: Wikimedia Foundation, Inc.;
Harpagophytum procumbens suppresses lipopolysaccharide-stimulated expressions of cyclooxygenase-2 and inducible nitric oxide synthase in fibroblast cell line L929.
(2009). Home > Patient/Public Info > Complementary and Alternative Cancer Therapies > Essiac/Flor·Essence [Web article]. Vancouver: BC Cancer Agency; n.d. [Available at: www.bccancer.bc.ca/PPI/UnconventionalTherapies/ EssiacFlor%2aEssence.htm; cited February 1,
Increased cyclooxygenase-2 (c o x -2): a potential role in the pathogenesis of lymphoma.
(2008). National Institutes of Health, National Cancer Institute (n c i ). Cancer Topics > Complementary and Alternative Medicine > Specific Topics: Essiac/Flor·Essence [patient] > Essiac/Flor·Essence (p d q ): Patient Version [Web article]. Bethesda, MD: n c i ;
(2008). National Library of Medicine (n l m ) and the National Institutes of Health, MedlinePlus. Cancer Alternative Therapies [Web article].
No initial therapy for stage iii and iv non-Hodgkin’s lymphomas of favorable histologic types.
on behalf of the British National Lymphoma Investigation. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial.
(1997). on behalf of the Groupe d’Etude des Lymphomes de l’Adulte. Comparison in lowtumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires.
Phase iii study of r-c v p compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.
Spontaneous regression in non-Hodgkin’s lymphoma: clinical and pathogenetic considerations. Am J Hematol 1989;31:138–41. Correspondence to: Kenneth Scott Wilson,
Spontaneous regression in non-Hodgkin’s lymphoma.
(1980). Spontaneous regression of non-Hodgkin’s lymphoma: a report of nine cases.
The effect of cele- The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
(1984). The natural history of initially untreated low-grade non-Hodgkin’s lymphomas.
(1991). The natural history of low grade non-Hodgkin’s lymphoma and the impact of a no initial treatment policy on survival.
The prevalence of complementary/ alternative medicine in cancer. A systematic review.
(1988). The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol